Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- Houston Methodist researchers found that brain regions experiencing ARIA-E swelling from Alzheimer's drugs like lecanemab and donanemab showed significantly greater amyloid plaque clearance compared to non-swollen areas. - The study analyzed PET scans from patients with moderate to severe brain swelling and found that 80% showed more substantial amyloid clearing in swollen regions, suggesting ARIA-E may indicate strong local treatment activity. - These findings could reframe ARIA-E from being viewed solely as an adverse side effect to a potential biomarker of therapeutic efficacy in amyloid-targeting treatments. - Researchers propose that the swelling occurs due to increased vascular permeability allowing higher drug concentrations to reach and dissolve amyloid clumps more effectively.
- The Coalition for Epidemic Preparedness Innovations (CEPI) has awarded up to $16 million to a Korean consortium led by the International Vaccine Institute to develop the world's first mRNA vaccine against Severe Fever with Thrombocytopenia Syndrome (SFTS). - The project utilizes artificial intelligence and structure-based design to create vaccine candidates using ST Pharm's proprietary SmartCap® and STLNP® platform technologies, marking the first time an SFTS vaccine will be tested in humans. - SFTS, transmitted by ticks in East Asia, causes high fever, thrombocytopenia, and potential multiple organ failure with no current commercial vaccine available. - The research aims to establish a prototype vaccine for the Phenuivirus family that could accelerate development of vaccines against similar emerging viruses within 100 days during future outbreaks.
- A multidisciplinary team at VCU Massey Comprehensive Cancer Center and MD Anderson Cancer Center received a $7.3 million U.S. Department of Defense grant to fund a novel clinical trial for metastatic triple-negative breast cancer. - The trial will test the combination of naxitamab, targeting the newly identified GD2 marker on cancer stem cells, with FDA-approved sacituzumab govitecan to overcome treatment resistance. - GD2 is overexpressed in more than half of TNBC tumors and is found on cancer stem cells that contribute to cell proliferation, metastasis, and worse patient outcomes. - This represents the first attempt to overcome TNBC's resistance to sacituzumab govitecan by eliminating breast cancer stem cells, potentially leading to more durable treatment responses.
